- Home
- CRDL vs ATOS Comparison
CRDL vs ATOS Comparison
Compare CRDL & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- ATOS
- Stock Information
- Founded
- CRDL 2017
- ATOS 2009
- Country
- CRDL Canada
- ATOS United States
- Employees
- CRDL N/A
- ATOS N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- CRDL Health Care
- ATOS Health Care
- Exchange
- CRDL Nasdaq
- ATOS Nasdaq
- Market Cap
- CRDL 104.5M
- ATOS 113.7M
- IPO Year
- CRDL N/A
- ATOS 2012
- Fundamental
- Price
- CRDL $1.23
- ATOS $0.87
- Analyst Decision
- CRDL Strong Buy
- ATOS Strong Buy
- Analyst Count
- CRDL 3
- ATOS 3
- Target Price
- CRDL $9.00
- ATOS $7.00
- AVG Volume (30 Days)
- CRDL 298.3K
- ATOS 826.7K
- Earning Date
- CRDL 11-14-2024
- ATOS 11-12-2024
- Dividend Yield
- CRDL N/A
- ATOS N/A
- EPS Growth
- CRDL N/A
- ATOS N/A
- EPS
- CRDL N/A
- ATOS N/A
- Revenue
- CRDL N/A
- ATOS N/A
- Revenue This Year
- CRDL N/A
- ATOS N/A
- Revenue Next Year
- CRDL N/A
- ATOS N/A
- P/E Ratio
- CRDL N/A
- ATOS N/A
- Revenue Growth
- CRDL N/A
- ATOS N/A
- 52 Week Low
- CRDL $0.96
- ATOS $0.77
- 52 Week High
- CRDL $3.12
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- CRDL 35.88
- ATOS 34.91
- Support Level
- CRDL $1.17
- ATOS $0.91
- Resistance Level
- CRDL $1.30
- ATOS $0.94
- Average True Range (ATR)
- CRDL 0.08
- ATOS 0.06
- MACD
- CRDL 0.00
- ATOS 0.00
- Stochastic Oscillator
- CRDL 17.65
- ATOS 24.67
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.